Cecilia Bukutu
Research Subjects
Research Interests
Cecilia Bukutu has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Sunita Vohra
University of Alberta
15 shared publications - Larissa Shamseer
Centre for Journalology, Ottawa Hospital Research Institute, Ottawa, ON, K1H 8L6, Canada
8 shared publications - Jane Anderson
Homerton University Hospital London UK
7 shared publications - Jonathan Elford
City University London
7 shared publications Margaret Sampson
Library Services, Children's Hospital of Eastern Ontario, Canada
5 shared publications- Christopher H. Schmid
Department of Biostatistics, Brown University School of Public Health, Providence, Rhode Island
4 shared publications
Latest Publications
- 2 November 2016
- Published by Taylor & Francis in Child Care in Practice
- Vol. 23 (4) , 404-416
Adults’ Knowledge of Child Development in Alberta, Canada: Comparing the Level of Knowledge of Adults in Two Samples in 2007 and 2013
Parents and non-parental adults who interact with children influence child development. This study evaluates the knowledge of child development in two large and diverse samples of adults from Alberta in 2007 and 2013. Telephone interviews were completed by two random samples (1,443 in 2007; 1,451 in 2013). Participants were asked when specific milestones in physical, cognitive, emotional and social domains typically occur (age birth to six years). Data were analysed using univariate and multivariate techniques. Linear logistic regression models were used to examine factors associated with knowledge and differences between the two samples while adjusting for differences and covariates. Adults’ knowledge was overall poor (<25% correct responses), but notably higher for physical (48% in 2007, 44% in 2013) than social, cognitive or emotional milestones (≤21% in all cases). Knowledge was lower in the 2013 than the 2007 sample (23% in 2007, 21% in 2013), and in particular for mothers after adjusting for location and income (24% in 2007, 22% in 2013). Evidence of low knowledge may have important education and policy implications. Factors such as availability of child development evidence-based information, parental stress and access to quality childcare might play a role in the low levels of knowledge.
- 2 November 2016
- Published by Taylor & Francis in Child Care in Practice
- Vol. 23 (4) , 404-416
Adults’ Knowledge of Child Development in Alberta, Canada: Comparing the Level of Knowledge of Adults in Two Samples in 2007 and 2013
Parents and non-parental adults who interact with children influence child development. This study evaluates the knowledge of child development in two large and diverse samples of adults from Alberta in 2007 and 2013. Telephone interviews were completed by two random samples (1,443 in 2007; 1,451 in 2013). Participants were asked when specific milestones in physical, cognitive, emotional and social domains typically occur (age birth to six years). Data were analysed using univariate and multivariate techniques. Linear logistic regression models were used to examine factors associated with knowledge and differences between the two samples while adjusting for differences and covariates. Adults’ knowledge was overall poor (<25% correct responses), but notably higher for physical (48% in 2007, 44% in 2013) than social, cognitive or emotional milestones (≤21% in all cases). Knowledge was lower in the 2013 than the 2007 sample (23% in 2007, 21% in 2013), and in particular for mothers after adjusting for location and income (24% in 2007, 22% in 2013). Evidence of low knowledge may have important education and policy implications. Factors such as availability of child development evidence-based information, parental stress and access to quality childcare might play a role in the low levels of knowledge.
- 1 August 2016
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 76, 47-56
N-of-1 trials are a tapestry of heterogeneity
- 1 August 2016
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 76, 47-56
N-of-1 trials are a tapestry of heterogeneity
- Open Access
- 1 August 2016
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 76, 18-46
CONSORT extension for reporting N-of-1 trials (CENT) 2015: explanation and elaboration
- 1 August 2016
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 76, 18-46
Open AccessCONSORT extension for reporting N-of-1 trials (CENT) 2015: explanation and elaboration
- Open Access
- 1 August 2016
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 76, 9-17
CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement
- 1 August 2016
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 76, 9-17
Open AccessCONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement
- 1 January 2016
- Published by Springer Nature
- p. 1949-1974
Complementary and Alternative Treatments for Renal Diseases
- 1 January 2016
- Published by Springer Nature
- p. 1949-1974
Complementary and Alternative Treatments for Renal Diseases
- Open Access
CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement
N-of-1 trials provide a mechanism for making evidence based treatment decisions for an individual patient. They use key methodological elements of group clinical trials to evaluate treatment effectiveness in a single patient, for situations that cannot always accommodate large scale trials: rare diseases, comorbid conditions, or in patients using concurrent therapies. Improvement in the reporting and clarity of methods and findings in N-of-1 trials is essential for reader to gauge the validity of trials and to replicate successful findings. A CONSORT extension for N-of-1 trials (CENT 2015) provides guidance on the reporting of individual and series of N-of-1 trials. CENT provides additional guidance for 14 of the 25 items of the CONSORT 2010 checklist and recommends a diagram for depicting an individual N-of-1 trial and modifies the CONSORT flow diagram to address the flow of a series of N-of-1 trials. The rationale, development process, and CENT 2015 checklist and diagrams are reported in this document.
Open AccessCONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement
N-of-1 trials provide a mechanism for making evidence based treatment decisions for an individual patient. They use key methodological elements of group clinical trials to evaluate treatment effectiveness in a single patient, for situations that cannot always accommodate large scale trials: rare diseases, comorbid conditions, or in patients using concurrent therapies. Improvement in the reporting and clarity of methods and findings in N-of-1 trials is essential for reader to gauge the validity of trials and to replicate successful findings. A CONSORT extension for N-of-1 trials (CENT 2015) provides guidance on the reporting of individual and series of N-of-1 trials. CENT provides additional guidance for 14 of the 25 items of the CONSORT 2010 checklist and recommends a diagram for depicting an individual N-of-1 trial and modifies the CONSORT flow diagram to address the flow of a series of N-of-1 trials. The rationale, development process, and CENT 2015 checklist and diagrams are reported in this document.
- Open Access
CONSORT extension for reporting N-of-1 trials (CENT) 2015: Explanation and elaboration
N-of-1 trials are a useful tool for clinicians who want to determine the effectiveness of a treatment in a particular individual. The reporting of N-of-1 trials has been variable and incomplete, hindering their usefulness in clinical decision making and by future researchers. This document presents the CONSORT (Consolidated Standards of Reporting Trials) extension for N-of-1 trials (CENT 2015). CENT 2015 extends the CONSORT 2010 guidance to facilitate the preparation and appraisal of reports of an individual N-of-1 trial or a series of prospectively planned, multiple, crossover N-of-1 trials. CENT 2015 elaborates on 14 items of the CONSORT 2010 checklist, totalling 25 checklist items (44 sub-items), and recommends diagrams to help authors document the progress of one participant through a trial or more than one participant through a trial or series of trials, as applicable. Examples of good reporting and evidence based rationale for CENT 2015 checklist items are provided.
Open AccessCONSORT extension for reporting N-of-1 trials (CENT) 2015: Explanation and elaboration
N-of-1 trials are a useful tool for clinicians who want to determine the effectiveness of a treatment in a particular individual. The reporting of N-of-1 trials has been variable and incomplete, hindering their usefulness in clinical decision making and by future researchers. This document presents the CONSORT (Consolidated Standards of Reporting Trials) extension for N-of-1 trials (CENT 2015). CENT 2015 extends the CONSORT 2010 guidance to facilitate the preparation and appraisal of reports of an individual N-of-1 trial or a series of prospectively planned, multiple, crossover N-of-1 trials. CENT 2015 elaborates on 14 items of the CONSORT 2010 checklist, totalling 25 checklist items (44 sub-items), and recommends diagrams to help authors document the progress of one participant through a trial or more than one participant through a trial or series of trials, as applicable. Examples of good reporting and evidence based rationale for CENT 2015 checklist items are provided.
- Open Access
- 29 May 2012
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 12 (1) , 70
Rhodiola rosea for physical and mental fatigue: a systematic review
Background: Rhodiola rosea (R. rosea) is grown at high altitudes and northern latitudes. Due to its purported adaptogenic properties, it has been studied for its performance-enhancing capabilities in healthy populations and its therapeutic properties in a number of clinical populations. To systematically review evidence of efficacy and safety of R. rosea for physical and mental fatigue. Methods: Six electronic databases were searched to identify randomized controlled trials (RCTs) and controlled clinical trials (CCTs), evaluating efficacy and safety of R. rosea for physical and mental fatigue. Two reviewers independently screened the identified literature, extracted data and assessed risk of bias for included studies. Results: Of 206 articles identified in the search, 11 met inclusion criteria for this review. Ten were described as RCTs and one as a CCT. Two of six trials examining physical fatigue in healthy populations report R. rosea to be effective as did three of five RCTs evaluating R. rosea for mental fatigue. All of the included studies exhibit either a high risk of bias or have reporting flaws that hinder assessment of their true validity (unclear risk of bias). Conclusion: Research regarding R. rosea efficacy is contradictory. While some evidence suggests that the herb may be helpful for enhancing physical performance and alleviating mental fatigue, methodological flaws limit accurate assessment of efficacy. A rigorously-designed well reported RCT that minimizes bias is needed to determine true efficacy of R. rosea for fatigue.
- 29 May 2012
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 12 (1) , 70
Open AccessRhodiola rosea for physical and mental fatigue: a systematic review
Background: Rhodiola rosea (R. rosea) is grown at high altitudes and northern latitudes. Due to its purported adaptogenic properties, it has been studied for its performance-enhancing capabilities in healthy populations and its therapeutic properties in a number of clinical populations. To systematically review evidence of efficacy and safety of R. rosea for physical and mental fatigue. Methods: Six electronic databases were searched to identify randomized controlled trials (RCTs) and controlled clinical trials (CCTs), evaluating efficacy and safety of R. rosea for physical and mental fatigue. Two reviewers independently screened the identified literature, extracted data and assessed risk of bias for included studies. Results: Of 206 articles identified in the search, 11 met inclusion criteria for this review. Ten were described as RCTs and one as a CCT. Two of six trials examining physical fatigue in healthy populations report R. rosea to be effective as did three of five RCTs evaluating R. rosea for mental fatigue. All of the included studies exhibit either a high risk of bias or have reporting flaws that hinder assessment of their true validity (unclear risk of bias). Conclusion: Research regarding R. rosea efficacy is contradictory. While some evidence suggests that the herb may be helpful for enhancing physical performance and alleviating mental fatigue, methodological flaws limit accurate assessment of efficacy. A rigorously-designed well reported RCT that minimizes bias is needed to determine true efficacy of R. rosea for fatigue.
- 1 April 2009
- Published by American Academy of Pediatrics (AAP) in Pediatrics in Review
- Vol. 30 (4) , e29-e33
Complementary, Holistic, and Integrative Medicine: Fish Oils and Neurodevelopmental Disorders
- 1 April 2009
- Published by American Academy of Pediatrics (AAP) in Pediatrics in Review
- Vol. 30 (4) , e29-e33
Complementary, Holistic, and Integrative Medicine: Fish Oils and Neurodevelopmental Disorders
- 1 February 2009
- Published by American Academy of Pediatrics (AAP) in Pediatrics in Review
- Vol. 30 (2) , 75-78
Complementary, Holistic, and Integrative Medicine: Fever
- 1 February 2009
- Published by American Academy of Pediatrics (AAP) in Pediatrics in Review
- Vol. 30 (2) , 75-78
Complementary, Holistic, and Integrative Medicine: Fever